Evidence map›Paper›PMID 35418803›Full record

ArticleTransplant international : official journal of the European Society for Organ Transplantation2022

Impact of COVID-19 on Global Kidney Transplantation Service Delivery: Interim Report.

Vassilios Papalois, Camille N Kotton, Klemens Budde, Julian Torre-Cisneros, Davide Croce, Fabian Halleck, Stéphane Roze, Paolo Grossi

Open access · goldAbstract read
In one paragraph

Article in Transplant international : official journal of the European Society for Organ Transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Back to the Future With Co-Stimulation Blockade.Transplant international : official journal of the European Society for Organ Transplantation · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Vassilios PapaloisRenal and Transplant Directorate, Imperial College Healthcare NHS Trust, London, United Kingdom.
Camille N KottonInfectious Diseases Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Klemens BuddeDepartment of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.
Julian Torre-CisnerosMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), Reina Sofía University Hospital, University of Cordoba, Cordoba, Spain.
Davide CroceResearch Centre in Health Economics and Healthcare Management, Carlo Cattaneo University, Castellanza, Italy.
Fabian HalleckDepartment of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.
Stéphane RozeVyoo Agency, Health-Economics Department, Villeurbanne, France.
Paolo GrossiDepartment of Infectious Diseases, University of Insubria, Varese, Italy.
Charité - Universitätsmedizin Berlin · DEFondazione Audiologica Varese · ITInstituto de Salud Carlos III · ESOffice of Infectious Diseases · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article gives a personal, historical, account of the impact of the COVID-19 pandemic on transplantation services. The content is based on discussions held at two webinars in November 2020, at which kidney transplantation experts from prestigious institutions in Europe and the United States reflected on how the pandemic affected working practices. The group discussed adaptations to clinical care (i.e., ceasing, maintaining and re-starting kidney transplantations, and cytomegalovirus infection management) across the early course of the pandemic. Discussants were re-contacted in October 2021 and asked to comment on how transplantation services had evolved, given the widespread access to COVID-19 testing and the roll-out of vaccination and booster programs. By October 2021, near-normal life and service delivery was resuming, despite substantial ongoing cases of COVID-19 infection. However, transplant recipients remained at heightened risk of COVID-19 infection despite vaccination, given their limited response to mRNA vaccines and booster dosing: further risk-reduction strategies required exploration. This article provides a contemporaneous account of these different phases of the pandemic from the transplant clinician's perspective, and provides constructive suggestions for clinical practice and research.

Indexed as

COVID-19Kidney TransplantationCOVID-19 TestingHumansPandemicsSARS-CoV-2United States2020COVID-19 pandemiccytomegalovirus managementhistorical recordkidney transplantationservice delivery

Identifiers

PMID35418803
PMCPMC8996250
OpenAlexW4220806722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.